Could semiquantitative FDG analysis add information to the prognosis in patients with stage II/III breast cancer undergoing neoadjuvant treatment?
Laura Evangelista(Istituto Oncologico Veneto), PierFranco Conte(University of Padua), Valentina Guarneri(Istituto Oncologico Veneto), Silvia Michieletto(Istituto Oncologico Veneto), Enrico Orvieto(AULSS 2 Marca Trevigiana), Tania Saibene(Istituti di Ricovero e Cura a Carattere Scientifico), Anna Rita Cervino(Istituto Oncologico Veneto), Bozza Fernando(Istituto Oncologico Veneto), Cristina Ghiotto(Istituto Oncologico Veneto)
Cited by 17
Related Papers
Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study
|Journal of Clinical Oncology|2000|2.3k
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group.
|IRIS UNIMORE (University of Modena and Reggio Emilia)|2005|1.6k
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
|JAMA Oncology|2019|1k
Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations
|New England Journal of Medicine|2020|879
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
|Annals of Oncology|2023|830